Pfizer reiterated by Bear Stearns at outperform

Bear Stearns analyst John T. Boris reiterated Pfizer Inc. at an outperform rating and a price target of $30 based on the company's ability to transition to a revenue-driven double-digit earnings per share growth in 2007. Pfizer's next wave of new product opportunities will be launched through a leaner cost structure. Shares of the New York pharmaceutical company were down 26 cents, or 1.04%, at $24.71 on volume of 51,649,500 shares versus the three-month running average of 39,843,800 shares. (NYSE: PFE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.